Loading
Baltimore gynaecologic oncologist who led the trial showing that adding trastuzumab to chemotherapy helps women with HER2-positive uterine serous carcinoma, an aggressive form of endometrial cancer.
Amanda Nickles Fader is a gynaecologic oncologist at Johns Hopkins. She was first author of the 2018 Journal of Clinical Oncology report of the randomised phase 2 trial in which adding trastuzumab to carboplatin and paclitaxel lengthened progression-free survival in advanced or recurrent HER2/neu-positive uterine serous carcinoma, a result that entered guidelines. Her research also covers minimally invasive surgery and rare gynaecological cancers.
| Title | Journal | Year |
|---|---|---|
| Carboplatin-paclitaxel with or without trastuzumab in HER2-positive advanced or recurrent uterine serous carcinoma | Journal of Clinical Oncology | 2018 |
Shares Endometrial cancer and the tags endometrial, gynaecological, trialist.
Shares Endometrial cancer and the tags endometrial, gynaecological, trialist.
Shares Endometrial cancer and the tags endometrial, gynaecological, trialist.
Shares Endometrial cancer and the tags endometrial, trialist.
Shares Endometrial cancer and the tags endometrial, trialist.
Shares the tags gynaecological, trialist.
Shares the tags gynaecological, trialist.
Shares the tags gynaecological, trialist.